Medtronic’s Evolut trial outcome could alter US TAVR market: GlobalData

Medtronic has released results from the two-year point of a clinical trial comparing its Evolut to Edwards Lifesciences’ SAPIEN. The results revealed that the Evolut showed superior performance to the SAPIEN. Specifically, the Evolut showed significantly less BVD, five times less prosthetic valve thrombosis, and nine times less hemodynamic structural valve dysfunction. The clinical trial’s final results could shake up the US transcatheter aortic valve replacement (TAVR) market, says GlobalData.

According to GlobalData’s US Healthcare Facility Invoicing Database, Edwards Lifesciences is currently the market leader and holds over 60 per cent of the US TAVR market.

The Evolut clinical trial will continue to run until it reaches five years in length. Following the results, healthcare facilities might make the switch from buying from the market leader to buying a potentially superior product, bringing a change in the TAVR market share.

Amy Paterson, Medical Analyst, GlobalData, comments, “The trial results could bring a market shift, with Medtronic taking market share from Edwards. However, healthcare facilities might not be ready to make the shift at this point in the clinical trial. There are also many factors involved in purchasing choices such as price and ease of use.”

The preliminary results look promising for the Evolut for specific patients. The trial consists of mostly women, who have symptomatic severe aortic stenosis and small aortic annulus.

Paterson concludes, “For patients who fit into the trial category, the Evolut may become the preferred choice of healthcare professionals.”